• 9 May 2016

    Arsanis, Inc., a clinical-stage biopharmaceutical company focused on the development of targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, today announced that Rene Russo, Pharm.D., BCPS, has been promoted to president and chief executive officer.

  • 9 May 2016

    Axonics Modulation Technologies, Inc., developer of the first rechargeable implantable Sacral Neuromodulation System (SNM) for the treatment of urinary and fecal dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics six U.S. patents relating to implantable neuromodulation technology and recharging systems.

  • 5 May 2016

    LAGUNA HILLS, Calif., May 5, 2016-/Globe Newswire/-Sonendo®, Inc., the developer of a disruptive technology for the endodontic marketplace,  announced today that the GentleWave® System, has been chosen as a finalist in this year’s Medical Design Excellence Awards (MDEA) for its compelling and innovative design. MDEA are the premier awards for the medical technology industry that honor the highest caliber medical devices on the market today.

  • 29 April 2016

    Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently in a Phase II clinical study in Wilson Disease patients.

  • 30 March 2016

    Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune disease, today announced that it has recruited the first patient  into a Phase I monotherapy trial of its lead programme, IMCgp100, for the treatment of uveal melanoma.